multi-omics
(6)
Jonathan Wang
Jonathan Wang is the co-founder and CEO of Watershed (Watershed Informatics / Watershed Bio), a Cambridge-based biocomputing platform that lets biologists run complex multi-omics analyses without writing code. An MIT computer scientist who once built a high-frequency trading hedge fund out of his dorm room, Wang co-founded Domeyard before pivoting to biology in 2019, applying the speed-obsessed engineering culture of quant finance to the sprawling data problem of modern drug discovery. Watershed raised a $14.5M Series A led by Canvas Ventures in 2023 and aims to become the dominant biocomputing platform for the world's scientists.
Clayton Rabideau
Clayton Rabideau is the founder and CEO of Syntensor, a San Francisco startup building foundation models and mechanistic simulations of human cell biology to predict drug efficacy, toxicity, and the hidden causes of clinical-trial failure. A Cambridge PhD in chemical engineering and biotechnology, he works at the seam between dynamical-systems mathematics and genomics - a co-author on HyenaDNA, the NeurIPS 2023 spotlight that stretched genomic language models to a million bases of context. He is trying to make biology as fast, iterative, and programmable as software.
Alice Zhang
Alice Zhang is the CEO and co-founder of Verge Genomics (now Verge Labs), a San Francisco biotech she started in 2015 after walking away from an MD/PhD program at UCLA. She built a company that pairs machine learning with one of the largest collections of human brain tissue to find drug targets for diseases like ALS, Parkinson's and Alzheimer's. A Princeton molecular biology graduate, Soros Fellow and Forbes 30 Under 30 honoree, Zhang turned her inexperience into what she calls a 'superpower,' raising more than $130 million and partnering with Eli Lilly and AstraZeneca before pivoting the company toward selling its data and insights to pharma in 2025.
Vik Vaz
Vik Vaz is a physician-turned-executive who became CEO and President of San Diego multi-omics biotech Pleno Inc. in December 2024, arriving the same day the company closed a $25M Series B. Trained as a surgeon and interventional oncologist, he later ran strategy and companion diagnostics at Illumina and was a partner at both McKinsey and Boston Consulting Group. At Pleno he is commercializing the RAPTOR platform, which uses proprietary Hypercoding technology to detect DNA, RNA and protein targets in a single sample at high speed and low cost.
Abhishek Jha
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
Yongwei Zhang
Yongwei Zhang is the CEO of Complete Genomics and MGI Americas, leading one of the most ambitious efforts to make whole-genome sequencing fast, accurate, and affordable at scale. With a PhD in Mechanical Engineering from Johns Hopkins and dual bachelor's degrees from Tsinghua University, Zhang brings a rare blend of optics precision, software fluency, and entrepreneurial grit to the genomics frontier. He architected the DNBSEQ sequencing platform series now used by over 2,600 researchers in 100 countries, and has positioned Complete Genomics as a formidable challenger to Illumina's market dominance - at a fraction of the cost.